Showing 1 - 5 results of 5 for search 'Huide Zhu', query time: 0.01s Refine Results
  1. 1
    Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.

    Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis. by Zhiwei Zheng, Huide Zhu, Ling Fang

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.

    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. by Zhiwei Zheng, Huide Zhu, Ling Fang

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer

    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer by Zhiwei Zheng, Huide Zhu, Ling Fang

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis

    Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis by Longfeng Zhang, Hongcai Chen, Huide Zhu, Zhiwei Zheng

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis

    Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis by Zhiwei Zheng, Hongfu Cai, Jingwen Lin, Huide Zhu

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: